RBC Capital Reiterates Outperform on 4D Molecular Therapeutics, Maintains $40 Price Target

Benzinga · 07/22/2024 13:56
RBC Capital analyst Luca Issi reiterates 4D Molecular Therapeutics (NASDAQ:FDMT) with a Outperform and maintains $40 price target.